Firm News

Briefing Policymakers: Tropical Forest Fires, Deadly Haze, and Human Rights During a Pandemic

Last month, Congressional staffers and allied NGO partners were invited to a virtual Hill briefing featuring international experts on the human and environmental impacts of deforestation, forest fires, and toxic haze during a global pandemic. 

Medicare and Medicaid at 55: The Fight Continues

When President Lyndon Johnson signed Medicare and Medicaid into law 55 years ago, he understood that a nation is judged not on how its most prosperous thrive, but on how it cares for its most vulnerable.

Transparency and FARA Compliance in Our Environmental Work

Waxman Strategies has registered under FARA, as the firm receives grant support (including for its work to support Mighty Earth campaigns) from non-profit organizations that are in turn funded by the Norwegian Agency for Development Cooperation (Norad).

Taking a Stand

At Waxman Strategies, we recognize systemic racism pervades our society. It impacts our personal biases and prejudices. And it impacts our institutions. The answer is not going to come from striving for color blindness, but from embracing and respecting different backgrounds. And we must not lose sight that white privilege exists and has existed since the dawn of our republic.

Building Capacity for Transformative Change in Health Care with Two New Policy Experts

Waxman Strategies is strengthening its firmwide capabilities in political advocacy, regulatory insight, and industry expertise with the appointment of Ruth McDonald and Kahaari Kenyatta to the health policy team.

Remaining Committed

During this historic moment for our country and the planet, we want to mark the moment and update our stakeholders on how we are navigating these uncertain times.

Waxman Strategies Publishes White Paper on Nonprofit Pharmaceutical Companies

Based on the input of experts and nonprofit leaders, our white paper describes challenges in five policy areas and provides a set of policy options for policymakers to consider which could improve the sustainability of the nonprofit model and help to reduce the burden of high prescription drug prices.

Henry Waxman Applauds Passage of H.R. 3

Today, the House of Representatives passed H.R. 3 – the Elijah E. Cummings Lower Drug Costs Now Act. Chairman Henry Waxman released the following statement in support of the bill’s passage.

Henry Waxman Debunks Pharmaceutical Industry Claims of Innovation Loss, Again

In a blog post for Health Affairs, Chairman Henry Waxman  debunks the age-old industry claim that lower drug costs mean a loss of drug innovation, noting they made the same unsubstantiated claim back in the 1980s during debate on the Hatch-Waxman Act.

Henry Waxman Discusses The Lower Drug Costs Now Act in Health Affairs

In a piece written for Health Affairs this week, our Chairman Henry Waxman discusses the broken pharmaceutical marketplace, how empowering Medicare to negotiate prices with the pharmaceutical industry will make prescription drugs more affordable for everyone, and why we need the Lower Drug Costs Now Act.